Compare JBGS & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBGS | TLRY |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 919.2M |
| IPO Year | 2017 | 2018 |
| Metric | JBGS | TLRY |
|---|---|---|
| Price | $14.98 | $6.17 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $17.00 | ★ $103.33 |
| AVG Volume (30 Days) | 496.3K | ★ 2.1M |
| Earning Date | 04-28-2026 | 04-07-2026 |
| Dividend Yield | ★ 4.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $498,598,000.00 | N/A |
| Revenue This Year | N/A | $7.39 |
| Revenue Next Year | N/A | $4.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.28 | $0.36 |
| 52 Week High | $24.30 | $15.70 |
| Indicator | JBGS | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 27.53 |
| Support Level | $14.21 | $1.00 |
| Resistance Level | $15.95 | $8.20 |
| Average True Range (ATR) | 0.46 | 0.33 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 79.58 | 0.33 |
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.